BIPHENYL AND PHENYLPYRIDINE COMPOUNDS AS KAT2A AND / OR KAT2B INHIBITORS

Abstract

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein ring A is a 5-6 membered phenyl or heteroaryl N-containing ring consisting of one or two N atoms and carbon atoms as ring members; L is a linker group, wherein the asterisk represents the point of attachment to ring A and the wavy line represents the point of attachment to R4, z is 0 or 1, q is 0, 1 or 2, each Q being independently -OH, -CH3 or halogen, and ring B is a C3-C6 cycloalkyl;one of R1 and R2 is H or a halogen and the other of R1 and R2 is a group of formula (E1-1), (E1-2), among others, wherein each asterisk represents the point of connection to ring A, m is 0 or 1, each of R5 and R6 is independently (i) H, (ii) a halogen, (iii) a C1-C6 alkyl optionally substituted with 1 to 3 halogens and 1 to 3 -OH groups, (iv) a C1-C3 deuterated alkyl, (v) a C2-C6 alkenyl or (vi) a C2-6 alkynyl, or R5 and R6 together form a C3-C6 cycloalkyl or a 4-6 membered heterocycloalkyl comprising at least one heteroatom selected from the group consisting of N, O and S, the C1 ring being a 5-6 membered N-containing heteroaryl optionally substituted with a group selected from (i) C1-C3 alkyl optionally substituted with 1 to 4 halogens, (ii) C2-C3 hydroxyalkyl and (iii) C3-C4 cycloalkyl; n is 1, 2 or 3;Each R3 is independently selected from the group consisting of (i) halogen, (ii) C1-C6 alkyl optionally substituted with 1 to 3 halogens, (iii) C2-C6 alkenyl, (iv) C2-C6 alkynyl, and (v) C3-C6 cycloalkyl optionally substituted with 1 to 4 halogens; and R4 is a 3- to 6-membered N-containing heterocycloalkyl optionally substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -OH, among others, wherein the attachment point to the L-linking group is on a carbon atom. The invention also relates to a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt thereof together with at least one pharmaceutically acceptable excipient. The compound of the present invention may be useful in the treatment, prevention, suppression and improvement of diseases, disorders and conditions, such as types of cancer.